 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
1 May 1993 | Volume 118 Issue 9 | Pages 674-680
Objective: To determine the extent to which lymphocytes, particularly those with the CD4 surface antigen, are a surrogate marker for the development of the acquired immunodeficiency syndrome (AIDS) in persons with asymptomatic human immunodeficiency virus (HIV) infection.
Design: Analysis of data from the AIDS Clinical Trials Group Protocol 019, a placebo-controlled, double-blind, randomized trial.
Setting: University-based referral centers.
Patients: Asymptomatic HIV-infected patients with 500 or fewer CD4+ cells/mm3 at baseline who were given placebo (350 patients) or one of two daily doses of zidovudine (725 patients).
Measurements: Baseline and interim measurements of CD4+ and other leukocytes were assessed. Patients were followed for progression to AIDS.
Results: Patients' lymphocyte levels were correlated with progression to AIDS (P < 0.001; relative risk for each depletion of 50 CD4+ cells/mm3, 1.75; 95% CI, 1.53 to 2.01); however, only a small portion (0% to 37%) of the effect of zidovudine on this progression was statistically explained by its effect on CD4+ lymphocyte levels. A substantial portion of zidovudine's effect on delaying progression to AIDS that was independent of the levels of these markers occurred within the first 16 weeks of therapy. In patients who had not progressed to AIDS by week 16, most of the subsequent zidovudine effect in reducing the risk for progression could be explained by its effect on net CD4+ percent (percentage of CD4+ lymphocytes among all leukocytes) for the first 16 weeks of therapy.
Conclusion: Levels of CD4+ lymphocytes are an incomplete surrogate marker for progression to AIDS, and the association is especially weak during the first 16 weeks of zidovudine therapy.
Author and Article Information
From McGill University, Montreal, Quebec, Canada; the Harvard School of Public Health, Boston, Massachusetts; the University of Colorado Health Science Center, Denver, Colorado; the University of California, San Francisco, California. A partial list of the institutions participating in the AIDS Clinical Trials Group appears in the Appendix.
ARTICLE
CD4+ Lymphocytes Are an Incomplete Surrogate Marker for Clinical Progression in Persons with Asymptomatic HIV Infection Taking Zidovudine
Requests for Reprints: Sungsub Choi, PhD, Department of Epidemiology and Biostatistics, McGill University, Purvis Hall, 1020 Pine Avenue West, Montreal, Quebec H3A 1A2, Canada.
Acknowledgments: This research is an activity of the AIDS Clinical Trials Group. The authors thank Song-Heng Liou for preparing the data, Donna Jacobsen for editorial assistance, and Daniel S. Stein, MD, for helpful comments.
Grant Support: By the Statistical and Data Analysis Center of the AIDS Clinical Trials Group, under NIAID Contract No. NO1-AI-95030. The Burroughs Wellcome Company partly funded editorial and word processing support.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  D. K. Benjamin Jr, S. Hirschfeld, C. K. Cunningham, and R. E. McKinney Jr Growth as a part of the composite endpoint in paediatric antiretroviral clinical trials J. Antimicrob. Chemother., October 1, 2004; 54(4): 701 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Molenberghs, T. Burzykowski, A. Alonso, and M. Buyse A perspective on surrogate endpoints in controlled clinical trials Statistical Methods in Medical Research, June 1, 2004; 13(3): 177 - 206. [Abstract] [PDF]
|
|
|
|
 |
|
 R. G. Holloway and A. W. Dick Clinical trial end points: On the road to nowhere? Neurology, March 12, 2002; 58(5): 679 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pia Sormani, P. Bruzzi, G. Comi, and M. Filippi MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients Neurology, February 12, 2002; 58(3): 417 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. G Becker and I. C Marschner Advances in medical statistics arising from the AIDS epidemic Statistical Methods in Medical Research, April 1, 2001; 10(2): 117 - 140. [Abstract] [PDF]
|
|
|
|
 |
|
 P. B. Gilbert, V. DeGruttola, S. M. Hammer, and D. R. Kuritzkes Virologic and Regimen Termination Surrogate End Points in AIDS Clinical Trials JAMA, February 14, 2001; 285(6): 777 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Churdboonchart, C. Sakondhavat, S. Kulpradist, B. I. Na Ayudthya, V. Chandeying, S. Rugpao, C. Boonshuyar, W. Sukeepaisarncharoen, W. Sirawaraporn, D. J. Carlo, et al. A Double-Blind, Adjuvant-Controlled Trial of Human Immunodeficiency Virus Type 1 (HIV-1) Immunogen (Remune) Monotherapy in Asymptomatic, HIV-1-Infected Thai Subjects with CD4-Cell Counts of >300 Clin. Vaccine Immunol., September 1, 2000; 7(5): 728 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B Gilbert Some statistical issues in the design of HIV-1 vaccine and treatment trials Statistical Methods in Medical Research, June 1, 2000; 9(3): 207 - 229. [Abstract] [PDF]
|
|
|
|
|
|
P. J. Easterbrook, R. L. Goodall, A. G. Babiker, L. M. Yu, D. Smith, D. A. Cooper, and B. G. Gazzard Are HIV-infected patients with rapid CD4 cell decline a subgroup who benefit from early antiretroviral therapy? J. Antimicrob. Chemother., March 1, 1999; 43(3): 379 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Aziz, P. Nishanian, R. Mitsuyasu, R. Detels, and J. L. Fahey Variables That Affect Assays for Plasma Cytokines and Soluble Activation Markers Clin. Vaccine Immunol., January 1, 1999; 6(1): 89 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Aziz, P. Nishanian, and J. L. Fahey Levels of Cytokines and Immune Activation Markers in Plasma in Human Immunodeficiency Virus Infection: Quality Control Procedures Clin. Vaccine Immunol., November 1, 1998; 5(6): 755 - 761. [Abstract] [Full Text]
|
|
|
|
|
|
J. L. Fahey Cytokines, Plasma Immune Activation Markers, and Clinically Relevant Surrogate Markers in Human Immunodeficiency Virus Infection Clin. Vaccine Immunol., September 1, 1998; 5(5): 597 - 603. [Full Text]
|
|
|
|
 |
|
 S. E. Lipshultz, K. A. Easley, E. J. Orav, S. Kaplan, T. J. Starc, J. T. Bricker, W. W. Lai, D. S. Moodie, K. McIntosh, M. D. Schluchter, et al. Left Ventricular Structure and Function in Children Infected With Human Immunodeficiency Virus : The Prospective P2C2 HIV Multicenter Study Circulation, April 7, 1998; 97(13): 1246 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. O'Brien, P. M. Hartigan, D. Martin, J. Esinhart, A. Hill, S. Benoit, M. Rubin, M. S. Simberkoff, and J. D. Hamilton Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDS N. Engl. J. Med., February 15, 1996; 334(7): 426 - 431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Volberding, S. W. Lagakos, J. M. Grimes, D. S. Stein, J. Rooney, T.-C. Meng, M. A. Fischl, A. C. Collier, J. P. Phair, M. S. Hirsch, et al. A Comparison of Immediate with Deferred Zidovudine Therapy for Asymptomatic HIV-Infected Adults with CD4 Cell Counts of 500 or More per Cubic Millimeter N. Engl. J. Med., August 17, 1995; 333(7): 401 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Piette, T. J. Wachtel, V. Mor, and K. Mayer The Impact of Age on the Quality of Life in Persons with HIV Infection J Aging Health, May 1, 1995; 7(2): 163 - 178. [Abstract] [PDF]
|
|
Article
